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The growing portfolio of maternal vaccines becoming available
offers a valuable lever to make a quantum shift in the maternal and
child health landscape.
The world has made tremendous strides in child survival, but we
are not there yet. Far too many neonates, approximately 600,000,
still do not survive infections every year [1]. The ﬁght to reduce
global maternal mortality has also made progress with a 45% reduc-
tion between 1990 and 2013. However, the current average of 210
maternal deaths per 100,000 live births is still unacceptable [2].
With such high numbers of persisting, mostly preventable, mater-
nal and neonatal deaths, something needs to change.
Maternal immunization is the missing link, adding to important
existing antenatal interventions, to protect both mother and infant
during some of the most vulnerable moments in both of their lives.
The success of the maternal and neonatal tetanus initiative
demonstrates that maternal immunization can work and can have
global impact [3]. In Bangladesh, for instance, maternal tetanus
immunization coverage increased from 4% in 1986 to 90% in 2001,
leading to a decrease in tetanus-related newborn deaths from 40
per 1000 live births to only 3 per 1000 over the same time period
[4].
In addition to maternal tetanus, used primarily in low- and
middle-income countries, inﬂuenza and pertussis vaccines are now
also recommended during pregnancy in some countries, includ-
ing the UK and US, and have successfully demonstrated impact in
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reducing illness and saving lives [5,6]. New vaccines, such as group
B streptococcus and respiratory syncytial virus (RSV), are also in the
pipeline, but they will need an investment in preparedness well in
advance of their delivery.
There have been bumps in the road and lessons continue to be
learned in the roll out of the maternal and neonatal tetanus elimi-
nation campaigns, and a growing body of research on determinants
of inﬂuenza and pertussis uptake during pregnancy, all of which is
an archive of knowledge to inform and support the introduction of
valuable new maternal vaccinations in different settings. One thing
is clear. Despite their proven efﬁcacy, maternal inﬂuenza and per-
tussis vaccines are not being accepted as widely as they could be
due to a range of issues, including inadequate information, lack
of—or hesitating—recommendation by the health provider, and
safety anxieties. Other barriers have included inadequate engage-
ment of the community, peers and trusted networks all of whom
inﬂuence decisions to vaccinate during pregnancy.
Last year, for instance, twenty year-old rumours about the
tetanus vaccine causing sterilization resurfaced in a press state-
ment issued by the Catholic Bishops of Kenya [7]. The issue that
prompted the concerns was perceived lack of transparency and
inadequate engagement of the religious leaders in the tetanus cam-
paign. “We  the Catholic Bishops in Kenya,” the press statement
read, “are concerned about the following issues regarding the ongo-
ing tetanus vaccination campaign: (1) there has not been adequate
stakeholder engagement for consultation both in the preparation
and implementation of the campaign. The Catholic Church has not
been engaged unlike other public health initiatives where we have
been invited to participate as a key stakeholder. (2) There has been
limited public awareness unlike other national health initiatives
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that are preceded by a public launch where the public can ask
questions. (3) Lack of public information on the rationale with a
background that has informed the initiative.” All of these concerns
underline the importance of ensuring that engagement is not only
at the level of those being targeted for vaccination, but also those
who inﬂuence and support their decisions—not only around vacci-
nation but also in their daily lives.
Context matters
Reviews of the global literature on factors inﬂuencing individ-
ual vaccine acceptance during pregnancy highlight a number of
issues that can inform strategies to support the introduction of new
maternal vaccines. Many of the themes which emerge are similar to
those raised around vaccines more generally: “Is the vaccine safe?
Is it effective? Do I really need this particular vaccine? And, can I
afford it?” In the case of maternal immunization, safety concerns
are often the most prominent, particularly related to any real or
perceived risks around the safe development of the foetus [8–10].
Building the conﬁdence of pregnant women to accept additional
vaccination means understanding their perspective and the mix  of
both concerns and supportive inﬂuences that surround them.
In even the most remote corners of the world, most women  have
at least one, and often more, interaction with a health care provider
or midwife during pregnancy [11]. And, one of the most important
inﬂuences in vaccination decisions is the recommendation of the
health provider. One study found that women who  had received
a recommendation to be vaccinated post-partum were 6.9 times
more likely to report intention to vaccinate [12], while a global
literature review reported that the studies reviewed showed that
mothers who had a supportive recommendation from their health
care provider were 20–100 times more likely to get the vaccine
under consideration [8].
But, what happens when the health care provider is not con-
ﬁdent? A number of studies have shown that while a positive
recommendation can leverage acceptance of a vaccination, hes-
itation or the absence of a recommendation on the part of the
health care provider or midwife can lead to non-acceptance. Build-
ing provider conﬁdence is therefore a key link in the conﬁdence
chain between women considering vaccination and the policies and
programmes that support their delivery.
The primary context for maternal immunization is antenatal
care, supported by family, trusted information sources and com-
munity members. The requirements already established for tetanus
maternal immunization programmes can provide a valuable sup-
port to the introduction of newer maternal vaccinations [13]. But,
beyond the infrastructural and policy requirements, building the
conﬁdence and engagement of the vaccinators, women  of repro-
ductive age, their families and community is key. Pregnancy and
child bearing in any culture is a celebrated, but sensitive, time.
Introducing maternal vaccination needs to consider the existing
context, preferences, and risk perceptions of the women–whether
in high, middle or low-income settings and in each unique religious
or socio-cultural context. Risk perceptions will also vary depending
on previous experience with vaccinations and familiarity with the
diseases being addressed. Most importantly, how women feel about
pregnancy and the other issues surrounding it need to be part of
the conversation as this emotional context will also be key in the
decision to vaccine [14].
Familiarity, ease of access, trust, and awareness of beneﬁts
and risks to minimize uncertainty, will all be important for the
sustained support of existing and new maternal vaccinations.
Examples where key community members have not been engaged,
leading to subsequent feelings of exclusion and the undermin-
ing of the vaccination programme [7], should be a lesson for the
future. With adequate engagement and conﬁdence building, mater-
nal immunization could become the new “normal”.
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